110 related articles for article (PubMed ID: 23770367)
1. WW domain-containing oxidoreductase is involved in upregulation of matrix metalloproteinase 9 by Epstein-Barr virus latent membrane protein 2A.
Lan YY; Wu SY; Lai HC; Chang NS; Chang FH; Tsai MH; Su IJ; Chang Y
Biochem Biophys Res Commun; 2013 Jul; 436(4):672-6. PubMed ID: 23770367
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9.
Lan YY; Hsiao JR; Chang KC; Chang JS; Chen CW; Lai HC; Wu SY; Yeh TH; Chang FH; Lin WH; Su IJ; Chang Y
J Virol; 2012 Jun; 86(12):6656-67. PubMed ID: 22514348
[TBL] [Abstract][Full Text] [Related]
3. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.
Ikeda M; Ikeda A; Longan LC; Longnecker R
Virology; 2000 Mar; 268(1):178-91. PubMed ID: 10683340
[TBL] [Abstract][Full Text] [Related]
4. WW- and SH3-domain interactions with Epstein-Barr virus LMP2A.
Longnecker R; Merchant M; Brown ME; Fruehling S; Bickford JO; Ikeda M; Harty RN
Exp Cell Res; 2000 Jun; 257(2):332-40. PubMed ID: 10837147
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway.
Stewart S; Dawson CW; Takada K; Curnow J; Moody CA; Sixbey JW; Young LS
Proc Natl Acad Sci U S A; 2004 Nov; 101(44):15730-5. PubMed ID: 15498875
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus latent membrane protein 2A upregulates UDP-glucose dehydrogenase gene expression via ERK and PI3K/Akt pathway.
Pan YR; Vatsyayan J; Chang YS; Chang HY
Cell Microbiol; 2008 Dec; 10(12):2447-60. PubMed ID: 18717819
[TBL] [Abstract][Full Text] [Related]
7. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
8. RECK is a target of Epstein-Barr virus latent membrane protein 1.
Liu LT; Peng JP; Chang HC; Hung WC
Oncogene; 2003 Nov; 22(51):8263-70. PubMed ID: 14614450
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
[TBL] [Abstract][Full Text] [Related]
10. Expression and characterization of N-terminal domain of Epstein-Barr virus latent membrane protein 2A in Escherichia coli.
Park SJ; Seo MD; Lee SK; Ikeda M; Longnecker R; Lee BJ
Protein Expr Purif; 2005 May; 41(1):9-17. PubMed ID: 15802216
[TBL] [Abstract][Full Text] [Related]
11. Identification of the WW domain-interaction sites in the unstructured N-terminal domain of EBV LMP 2A.
Seo MD; Park SJ; Kim HJ; Lee BJ
FEBS Lett; 2007 Jan; 581(1):65-70. PubMed ID: 17174309
[TBL] [Abstract][Full Text] [Related]
12. Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma.
Lee DC; Chua DT; Wei WI; Sham JS; Lau AS
Biomed Pharmacother; 2007 Oct; 61(9):520-6. PubMed ID: 17913445
[TBL] [Abstract][Full Text] [Related]
13. Tyrosines 60, 64, and 101 of Epstein-Barr virus LMP2A are not essential for blocking B cell signal transduction.
Swart R; Fruehling S; Longnecker R
Virology; 1999 Oct; 263(2):485-95. PubMed ID: 10544120
[TBL] [Abstract][Full Text] [Related]
14. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
15. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma.
Heussinger N; Büttner M; Ott G; Brachtel E; Pilch BZ; Kremmer E; Niedobitek G
J Pathol; 2004 Jun; 203(2):696-9. PubMed ID: 15141385
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas.
Zhang YW; Zhao XX; Tan C; Zhang ZG; Jiang Y; Chen JN; Wei HB; Xue L; Li HG; Du H; Shao CK
Oncotarget; 2015 Jan; 6(1):207-20. PubMed ID: 25402957
[TBL] [Abstract][Full Text] [Related]
17. A mutation in Epstein-Barr virus LMP2A reveals a role for phospholipase D in B-Cell antigen receptor trafficking.
Snyder MD; Pierce SK
Traffic; 2006 Aug; 7(8):993-1006. PubMed ID: 16882041
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.
Chang NS; Pratt N; Heath J; Schultz L; Sleve D; Carey GB; Zevotek N
J Biol Chem; 2001 Feb; 276(5):3361-70. PubMed ID: 11058590
[TBL] [Abstract][Full Text] [Related]
19. Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.
Fukuda M; Kawaguchi Y
J Virol; 2014 May; 88(9):5189-94. PubMed ID: 24554661
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of stem-like cell population comprises transformation ability of Epstein-Barr virus latent membrane protein 2A for non-transformed cells.
Nakaya T; Kikuchi Y; Kunita A; Ishikawa S; Matsusaka K; Hino R; Aburatani H; Fukayama M
Virus Res; 2013 Jun; 174(1-2):108-15. PubMed ID: 23524324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
